These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 1698674

  • 1. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy.
    Morelli E, Loon N, Meyer T, Peters W, Myers BD.
    Diabetes; 1990 Jan; 39(1):76-82. PubMed ID: 1698674
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
    Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara V, Remuzzi G, Remuzzi A.
    Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.
    Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G.
    J Clin Invest; 1990 Feb; 85(2):541-9. PubMed ID: 1688888
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome.
    Remuzzi A, Schieppati A, Battaglia C, Remuzzi G.
    Am J Kidney Dis; 1989 Sep; 14(3):170-7. PubMed ID: 2476029
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional nature of glomerular injury in progressive diabetic glomerulopathy.
    Tomlanovich S, Deen WM, Jones HW, Schwartz HC, Myers BD.
    Diabetes; 1987 May; 36(5):556-65. PubMed ID: 2436961
    [Abstract] [Full Text] [Related]

  • 10. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
    Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G.
    Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
    [Abstract] [Full Text] [Related]

  • 11. Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria.
    Narita T, Koshimura J, Suzuki K, Murata M, Meguro H, Fujita H, Kitazato H, Ito S.
    Tohoku J Exp Med; 1999 Oct; 189(2):117-33. PubMed ID: 10775055
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
    Cooper ME, Allen TJ, O'Brien RC, Papazoglou D, Clarke BE, Jerums G, Doyle AE.
    Diabetes; 1990 Dec; 39(12):1575-9. PubMed ID: 2245881
    [Abstract] [Full Text] [Related]

  • 14. Proteinuria and functional characteristics of the glomerular barrier in diabetic nephropathy.
    Carrie BJ, Myers BD.
    Kidney Int; 1980 May; 17(5):669-76. PubMed ID: 6157049
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin-converting enzyme activity.
    Duggan KA, Hodge G, Makarious MM, Charlesworth JA.
    Clin Sci (Lond); 1998 May; 94(5):511-6. PubMed ID: 9682674
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of proteinuria in diabetic nephropathy. II. A study of the size-selective glomerular filtration barrier.
    Friedman S, Jones HW, Golbetz HV, Lee JA, Little HL, Myers BD.
    Diabetes; 1983 May; 32 Suppl 2():40-6. PubMed ID: 6086024
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 18. In vivo visualization of the antialbuminuric effects of the angiotensin-converting enzyme inhibitor enalapril.
    Schießl IM, Kattler V, Castrop H.
    J Pharmacol Exp Ther; 2015 May 04; 353(2):299-306. PubMed ID: 25680709
    [Abstract] [Full Text] [Related]

  • 19. [ACE inhibitor effects on structure and function of the glomerular basement membrane].
    Hasslacher C, Bostedt-Kiesel A, Kempe HP.
    Klin Wochenschr; 1992 May 04; 69 Suppl 29():39-44. PubMed ID: 1614191
    [Abstract] [Full Text] [Related]

  • 20. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X, Matavelli LC, Ono H, Frohlich ED.
    Am J Physiol Renal Physiol; 2005 Oct 04; 289(4):F871-9. PubMed ID: 15900021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.